arrow
S

Satu Mustjoki

University of Helsinki
H-index:65
Citation Count:1.4万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly

RUNX1异常在原始细胞期慢性髓系白血病中诱导RNA结合蛋白SPATS2L,进而促进生长、存活和应激颗粒组装

Leukemia
IF13.4
2026-10-090
OAAI
Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT

异基因HSCT后适应性NK细胞和CMV特异性T细胞动态的单细胞分析

2026-06-250
OA
Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models

通过患者来源的离体模型对肾细胞癌肿瘤免疫微环境进行功能表征

2026-02-010
PRE
Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response

利用葡聚糖诱导的训练免疫促进巨噬细胞的表观遗传和代谢重组,以增强结直肠癌疫苗反应

2026-01-280
OA
Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

比较性临床前药物反应分析显示,T-原淋巴细胞白血病在已知的基因表达亚组之间没有差异。

2025-10-280
OAAI
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

粒细胞数量和成熟状态在诊断时预测慢性粒细胞白血病的无治疗缓解。

Leukemia
IF13.4
2025-09-160
OAAI
Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer

预测针对Wilms肿瘤1的抗原特异性T细胞免疫在血液系统癌症中的作用

Leukemia
IF13.4
2025-08-220
OAAI
Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses
2025-02-170
OAAI
Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma

双重特异性STAT3/5降解剂有效阻断急性髓系白血病和自然杀伤/T细胞淋巴瘤

2024-11-280
OAAI
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response

慢性粒细胞白血病的单细胞多组学分析将细胞异质性与治疗反应联系起来

2024-11-061
OA
Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

计算细胞形态学分析将骨髓红细胞比例鉴定为CML治疗无复发的生物标志物

BLOOD
IF23.1
2024-11-050
PRE
Predicting Antigen-Specific T Cell Immunity Against Wilms Tumor 1 in Hematologic Cancer

预测针对Wilms Tumor 1的抗原特异性T细胞免疫在血液系统癌症中的作用

BLOOD
IF23.1
2024-11-050
PRE
Ex vivo modeling of precision immuno-oncology responses in lung cancer

肺癌精确免疫肿瘤学反应的离体建模

2024-11-010
OAAI
Phase II study of nivolumab and relatlimab utilizing single cell analysis of circulating T cells reveals immune features associated with response to dual PD-1 and LAG-3 inhibition

一项利用循环T细胞单细胞分析的尼沃鲁单抗和瑞拉利单抗II期研究,揭示了与双重PD-1和LAG-3抑制反应相关的免疫特征

2024-09-010
PRE
Somatic mutations associate with clonal expansion of CD8+ T cells

体细胞突变与CD8 T细胞的克隆扩增有关

2024-06-071
OAAI
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

综合药物分析和CRISPR筛选确定BCR:: 慢性粒细胞白血病的ABL1-independent脆弱性

2024-05-012
OAAI
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia

过度活跃的STAT5劫持T细胞受体信号并驱动未成熟的T细胞急性淋巴细胞白血病

2024-04-151
OAAI
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment

呼吸复合物I在人肿瘤免疫微环境的外植体模型中调节树突状细胞的成熟

2024-04-111
OAAI
Single-cell characterisation of tissue homing CD4+and CD8+T cell clones in immune-mediated refractory arthritis

免疫介导的难治性关节炎中组织归巢CD4和CD8 T细胞克隆的单细胞表征

2024-04-090
OAAI
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial (Jan, 10.1038/s41375-024-02145-6 , 2024)

更正: 用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果 (1月,10.1038/s41375-024-02145-6,2024)

LEUKEMIA
IF13.4
2024-02-280
OAAI